Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA) filed a Form 8-K on December 11, 2025, reporting significant clinical trial developments for its gene therapy candidates. The filing addresses the resolution of a regulatory hold on the MyPEAK-1 trial for TN-201 and the release of interim data from the RIDGE-1 trial for TN-401.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on regulatory and clinical events. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Updates
- MyPEAK-1 (TN-201): The FDA removed a clinical hold previously placed on November 7, 2025. The hold was due to requests for protocol amendments regarding patient monitoring and immunosuppression management. The Company expects to resume dosing once protocol changes are implemented and anticipates no impact on data milestones or development timelines.
- RIDGE-1 (TN-401): Interim data was presented for three patients in Cohort 1 (follow-up ranging from Week 20 to Week 40).
- Safety: TN-401 was generally well tolerated with no dose-limiting toxicities. No thrombotic microangiopathy or cardiotoxicities were observed. One Grade 1 incidence of elevated troponin was categorized as a serious adverse event due to inpatient monitoring.
- Efficacy: Two of three patients showed significant improvements in electrical instability. Patient 1 saw a 46% decrease in premature ventricular contractions (PVCs), and Patient 2 saw an 89% decrease. Non-sustained ventricular tachycardias (NSVTs) were eliminated or stable in treated patients.
- Biomarkers: Serial biopsies confirmed TN-401 transduction to the heart with robust mRNA expression. PKP2 protein levels increased by a mean of 10% in Patients 1 and 2.
Guidance, Outlook, and Risks
Outlook: The Company expects to present two-year Cohort 1 and one-year Cohort 2 data for MyPEAK-1 in the first half of 2026. For RIDGE-1, one-year Cohort 1 data and early Cohort 2 data are also expected in the first half of 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include the potential failure of TN-401 to demonstrate safety or efficacy in future testing, variability in clinical trial results, patient enrollment challenges, and the Company's reliance on third parties and ability to raise additional funding.
Investor Verification Checklist
- Verify the timeline for resuming dosing in the MyPEAK-1 trial following the implementation of protocol amendments.
- Monitor the upcoming first-half 2026 data presentations for both MyPEAK-1 and RIDGE-1 to confirm long-term safety and efficacy trends.
- Review the Company's cash position and funding runway in subsequent filings (e.g., 10-Q or 10-K) as this 8-K does not provide financial data.
- Assess the variability in PKP2 protein expression results, specifically the confounding result in Patient 3, as further biopsies are analyzed.